We first characterized the temporal development of IPCs in detail and analyzed the transcriptome of early third instar IPCs.
The aim of this study was to provide evidence for further in vivo maturation of insulin-producing cells (IPCs) derived from human bone marrow-derived mesenchymal stem cells (HBM-MSCs).
Nowadays, unresolved obstacles associated with differentiation of stem cells into IPCs include maturation of the insulin secretory pathways and mechanisms responsible for sensing ambient glucose concentrations as well as lack of sufficient development of the insulin processing machinery [9, 10].
We tested four distinct culture media with or without serum for this extended culture, and all media permitted maturation of these β-cell properties in IPCs, indicating that the duration of culture is a key variable for promoting β-cell maturation in vitro.
In these IPCs, different TPMS architectures are used as reinforcing solid shells to increase the effective multifunctional properties of IPCs.
Figure 3 Morphological changes of IPCs, as detected by AFM.
In order to assess the function of IPCs, we tested the glucose-induced insulin secretion of IPCs and beta cells in vitro.
The percentage of IPCs among transplanted cells was small (≤3%).
linc Brn1b −/− mice demonstrate defects in proliferation of IPCs.
